The 5th China BioMed Innovation and Investment Conference is held in Suzhou, Jiangsu province from Sept 27 to 29. [Photo/WeChat account: gh_0411a8fd7895]
Guangzhou was recognized as a Biomedical Innovation City with the Most Investment Value in China at the 5th China BioMed Innovation and Investment Conference, which took place in Suzhou, Jiangsu province from Sept 27 to 29.
The selection was initiated by the R&D-based Pharmaceutical Association Committee of the China Association of Enterprises with Foreign Investment, as well as the China Pharmaceutical Innovation and Research Development Association.
They invited 20 experts to assess the cities and municipalities that feature biomedicine as one of their major industries across multiple indexes. Guangzhou was rated 3rd, with outstanding performance in infrastructure, supportive policies, R&D resources, innovation, financing, and enterprise strength.
In addition, the city made the top 10 in the rankings of Biomedical Innovation City, Medical Equipment Innovation City, and Medical Service Innovation City.
As a core city in the Guangdong-Hong Kong-Macao Greater Bay Area, Guangzhou boasts an aggregated development of its biomedical industry relying on platforms like Guangzhou Science City, China-Singapore Guangzhou Knowledge City, and Guangzhou International Bio Island.
Despite the COVID-19 outbreak, the output value of Guangzhou's pharmaceutical industry recorded a 6.5 percent year-on-year increase in the first seven months of this year, 7.4 percentage points higher than the same period last year.